The bio-tech market continues its disruption with Pfizer Inc playing a pivotal role from various developments. Analysts upgraded the prospects on the pharmaceutical giant, expecting a bullish momentum shortly. Pfizer's Oncology wins raise assessments of the valuation gap and potential future revenues. Notably, Market speculators are eyeing a rebound as vaccine-related propositions heat up. Detailed calculations reveal the intrinsic value of Pfizer Inc. while Goldman Sachs counts it amongst top healthcare stocks promising a strong buy in 2026. Sell or hold decisions on Pfizer stock sparked debates following a lukewarm Q4. Pfizer's shares witnessed growth after an analyst upgrade while debates on the valuation carried weight as shares traded near recent levels. Pfizer's late-stage Lyme vaccine progress and positive topline results from its Phase 3 TALAPRO-3 study are reshaping its investment case. Increased holdings by Czech National Bank and acquisitions by SG Americas Securities LLC showed institutional interest. However, Pfizer faced concerns related to risks, especially challenging the return on investment. Bullish predictions saw Pfizer potentially hitting $36 by year-end based on a key prostate cancer trial's payoff odds. Pfizer's affordability under $30, dividend yields, and robust pipeline highlighted it as a promising investment.
Pfizer Stocks News Analytics from Wed, 20 Aug 2025 07:00:00 GMT to Sat, 28 Mar 2026 19:08:35 GMT -
Rating 8
- Innovation 5
- Information 7
- Rumor -1
